The 1553-SPECTA translational research platform registered the 1000th patient on the 19th of November, at the Centre Hospitalier of Avignon. The platform opened for recruitment in February 2019, with the 1st patient registered in April 2019. 610 patients have received a molecular report so far.
We also have a new publication accepted for one of the SPECTA project Arcagen
We thank warmly all investigators who committed to the platform and are contributing to the success of the projects.
Three downstream projects are currently accessible to all SPECTA investigators:
– RP-1843 Arcagen is a collaborative project with the ERN EURACAN and Roche. It is recruiting patients with rare cancer, to gain understanding of the molecular landscape of rare cancer. The project has recruited 546 patients since May 31 2019. A free molecular report (FMI NGS panel) will be generated and shared with the clinician, for all eligible patients, within 4 weeks.
– RP-1759 AYA, is focusing on adolescent and young adults with CNS and Sarcoma tumours, and collaborating with DKFZ (Heidelberg) for the molecular analysis (WES, RNAseq and methylation assay). The Sarcoma cohort is now closed to recruitment (48 patients enrolled), and the CNS cohort has recruited 28 patients so far. Molecular reports and pathology review are shared with clinicians and discussed during a molecular tumor board.
– RP 1828 IMMUcan aims to generate broad molecular (WES and RNAseq) and cellular (multiplex IF and IMC) profiling data to understand the tumor and its microenvironment, and the impact of current therapeutic interventions. The project will recruit 3000 patients with head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC), and Breast cancers (BC). IMMUcan will also collaborate with external clinical trial. For each patient enrolled, a free molecular report is generated within 6 weeks, containing the clinically relevant molecular alterations. The IMMUcan consortium is an IMI2 funded initiative, with 26 partners from academic and pharma. For more information, please visit our website.
A new project is being developed: RP1920-Bioradon. We target recruitment start in Q2 2020. The project will assess the correlation between the molecular profiles of NSCLC patients and radon exposure.